Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2026-06-05 18:18:14 ET · period of report 2026-06-04 · accession 0001743658-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-05 18:18 | 2026-06-04 | XERS | HALKUFF DAWN | Dir | S - Sale | $6.09 | -20.0K | 95.0K | -17% | -$121.9K |
| DT | 2026-06-05 18:18 | 2026-06-04 | XERS | HALKUFF DAWN | Dir | A - Grant | $0.00 | +24.2K | 119.2K | +25% | $0 |
| DT | 2026-06-05 18:18 | 2026-06-04 | XERS | HALKUFF DAWN | Dir | A - Grant | $6.15 | +33.0K | 33.0K | New | +$202.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-04 | S | D | 20,000 | $6.09 | 95,000 | D | — | — | (F1) The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.960 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2026-06-04 | A | A | 24,193 | $0.00 | 119,193 | D | — | — | (F3) These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-06-04 | A | A | 32,996 | $6.15 | 32,996 | D | $6.15 · — to 2036-06-04 | 32,996 Common Stock | (F5) These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |